Elicio Therapeutics annual return on equity
2024
Elicio Therapeutics Return on Equity (ROE) Growth & History (ELTX)
Elicio Therapeutics's return on equity was −170,157.38% for fiscal 2024.
View full Elicio Therapeutics company overviewElicio Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −170,157.38% | — |
Elicio Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q3.23
Q4.23
Q1.24
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −252.83% | −56.13 pp |
| Q1 2026 | 2026-03-31 | −11,882.41% | — |
| Q4 2025 | 2025-12-31 | −283.13% | — |
| Q3 2025 | 2025-09-30 | −356.92% | — |
| Q2 2025 | 2025-06-30 | −196.70% | +252.58 pp |
| Q2 2024 | 2024-06-30 | −449.29% | — |
| Q1 2024 | 2024-03-31 | −145.63% | — |
| Q4 2023 | 2023-12-31 | −72.58% | — |
| Q3 2023 | 2023-09-30 | −57.86% | — |
| Q3 2021 | 2021-09-30 | −22.16% | — |
| Q2 2021 | 2021-06-30 | −20.13% | — |
| Q1 2021 | 2021-03-31 | −3,679.74% | — |
Elicio Therapeutics return on equity trends
The latest reported quarter, Q2 2026, shows −252.83%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elicio Therapeutics source filings ↗